Medical Therapy. Adverse Effects or Lack of Adverse Effects

Comparison of mortality and short-term outcomes between classic, intubation-surfactant-extubation, and less invasive surfactant administration methods of surfactant replacement therapy

Seung Yeon Kim, Jiseun Lim, Gyu-Hong ShimNowon Eulji Medical Center and Eulji University School of Medicine. Inje University Sanggye Paik Hospital.Republic of Korea Frontiers in PediatricsFront Pediatr 2023; 11DOI: 10.3389/fped.2023.1197607 AbstractBackground: Intubation-Surfactant-Extubation (InSurE) and less invasive surfactant administration (LISA) are alternative surfactant replacement therapy methods for reducing the complications associated with invasive mechanical ventilation. This study aimed […]

Comparison of mortality and short-term outcomes between classic, intubation-surfactant-extubation, and less invasive surfactant administration methods of surfactant replacement therapy Read More »

Comparing the efficacy and safety of low, medium, and high dosages of selexipag for treating pulmonary hypertension: A systematic review and meta-analysis

Shang Wang, Yi Yan, Jian Zhang, Ping Yuan, Ci-Jun Luo, Hong-Ling Qiu, Hui-Ting Li, Lan Wang, Tian-Lan Li, Rong Jianghanghai Pulmonary Hospital, School of Medicine, Tongji University. Shanghai Children’s Medical Center, National Children’s Medical Center, Shanghai Jiaotong University School of Medicine. The Second Affiliated Hospital of Chengdu Medical College. The Affiliated Hospital of Qingdao University.China

Comparing the efficacy and safety of low, medium, and high dosages of selexipag for treating pulmonary hypertension: A systematic review and meta-analysis Read More »

Acute pulmonary edema caused by epoprostenol infusion in a child with scimitar syndrome and pulmonary hypertension

Christian von Schnakenburg, Matthias Peuster, Kambiz Norozi, Markus Roebl, Michael Maibohm, Armin Wessel, Armin Christoph FinkGeorg-August-Universitaet Goettingen.Germany Pediatric Critical Care MedicinePediatr Crit Care Med 2003; 4: 111-114DOI: 10.1097/00130478-200301000-00023 AbstractIntroduction: Intravenous epoprostenol is frequently administered in adults and children for treatment of pulmonary hypertension. Although generally safe, pulmonary edema has been described in a few case reports of

Acute pulmonary edema caused by epoprostenol infusion in a child with scimitar syndrome and pulmonary hypertension Read More »

Safety and tolerability of continuous inhaled iloprost in critically ill pediatric pulmonary hypertension patients: A retrospective case series

Elizabeth Colglazier, Angelica J. Ng, Clair Parker, David Woolsey, Raymond Holmes, Allison Dsouza, Jasmine Becerra, Leah Stevens, Hythem Nawaytou, Roberta L. Keller, Jeffrey R. FinemanUniversity of California, San Francisco. Merck Sharp & Dohme LLC. Benioff Children’s Hospital. United States Pulmonary CirculationPulm Circ 2023; 13DOI: 10.1002/pul2.12289 AbstractInhaled iloprost (iILO) has shown efficacy in treating patients with hypoxic

Safety and tolerability of continuous inhaled iloprost in critically ill pediatric pulmonary hypertension patients: A retrospective case series Read More »

Real-world safety and effectiveness of inhaled nitric oxide therapy for pulmonary hypertension during the perioperative period of cardiac surgery: a post-marketing study of 2817 patients in Japan

Emi Matsugi, Shigeki Takashima, Shuhei Doteguchi, Tomomi Kobayashi, Motohiro OkayasuMallinckrodt Pharmaceuticals. Japan General Thoracic and Cardiovascular SurgeryGen Thorac Cardiovasc Surg 2023; DOI: 10.1007/s11748-023-01971-2 AbstractObjective: To evaluate the real-world safety and effectiveness of inhaled nitric oxide (INOflo® for Inhalation 800 ppm) for perioperative pulmonary hypertension associated with cardiac surgery in Japan.Methods: This was a prospective, non-interventional, all-case, post-marketing study of

Real-world safety and effectiveness of inhaled nitric oxide therapy for pulmonary hypertension during the perioperative period of cardiac surgery: a post-marketing study of 2817 patients in Japan Read More »

Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants

Matthew F. Pizzuto, Matthew M. Laughon, Wesley M. JacksonUniversity of North Carolina at Chapel Hill.United States Expert Opinion on PharmacotherapyExpert Opin Pharmacother 2023; DOI: 10.1080/14656566.2023.2257598 AbstractIntroduction: Pulmonary hypertension (PH) is a complex condition that encompasses an array of underlying disease processes and affects a diverse population of infants, including those with congenital heart disease, congenital diaphragmatic hernia,

Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants Read More »

Continuous Prostanoid Initiation in Severe Pulmonary Hypertension in the Pediatric Cardiac Intensive Care Unit

Richard U. Garcia, Asaad Beshish, Arene Butto, Usama Kanaan, Kevin MaherEmory University School of Medicine and Children’s Healthcare of Atlanta.United States Pediatric CardiologyPediatr Cardiol 2023; DOI: 10.1007/s00246-023-03282-y AbstractObjective: Limited data exists regarding prostanoid (PGI2) use in critically ill patients with pulmonary hypertension. (PH) in the pediatric cardiac intensive care unit (CICU) setting.Materials and methods: Single center, retrospective study

Continuous Prostanoid Initiation in Severe Pulmonary Hypertension in the Pediatric Cardiac Intensive Care Unit Read More »

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration

Jenna M. Faircloth, Neelam D. Bhatt, Corey A. Chartan, Ryan D. Coleman, Natalie Villafranco, Fadel E. Ruiz, Raysa Morales-Demori, Elise Whalen, Erin Ely, Rozmeen Fombin, Nidhy P. VargheseTexas Children’s Hospital and Baylor College of Medicine.United States Frontiers in PediatricsFront Pediatr 2023; 11DOI: 10.3389/fped.2023.1275389 AbstractThis corrects the article DOI: 10.3389/fped.2023.1050508. CategoryClass I. Idiopathic Pulmonary HypertensionClass I. Heritable

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration Read More »

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients

Julia McSweeney, Elizabeth Colglazier, Jasmine Becerra, Brienne Leary, Kathleen Miller‐Reed, Stephen Walker, Katy Tillman, Melissa Magness, Michelle Ogawa, Whitney Bannon, Tisha Kivett, Emma O. Jackson, Anne Davis, Cathy Shepard, Susan Richards, Elise Whalen, Shannon Engstrand, Zachary Di Pasquale, Jean A. ConnorBoston Children’s Hospital and Harvard Medical School. UCSF Benioff Children’s Hospital. Children’s Hospital of Colorado.

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients Read More »

Macitentan in the Young-Mid-term Outcomes of Patients with Pulmonary Hypertensive Vascular Disease treated in a Pediatric Tertiary Care Center

Sulaima Albinni, Julian Heno, Imre Pavo, Erwin Kitzmueller, Manfred Marx, Ina Michel‑BehnkeMedical University of Vienna.Austria Paediatric DrugsPaediatr Drugs 2023; 25: 467-481DOI: 10.1007/s40272-023-00573-y AbstractBackground: Pulmonary hypertension (PH) is a severe hemodynamic condition with high morbidity and mortality. Approved targeted therapies are limited for pediatric subjects, and treatments are widely adopted from adult algorithms. Macitentan is a safe and effective drug used for adult PH,

Macitentan in the Young-Mid-term Outcomes of Patients with Pulmonary Hypertensive Vascular Disease treated in a Pediatric Tertiary Care Center Read More »

Scroll to Top